Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies Teachey DT; Grupp SA; Brown VIBr J Haematol 2009[Jun]; 145 (5): 569-80The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulator of cell growth, protein synthesis, and cell-cycle progression through interactions with a number of signalling pathways, including PI3K/AKT, ras, TCL1, and BCR/ABL. Many haematological malignancies have aberrant activation of the mTOR and related signalling pathways. Accordingly, mTOR inhibitors, a class of signal transduction inhibitors that were originally developed as immunosuppressive agents, are being investigated in preclinical models and clinical trials for a number of haematological malignancies. Sirolimus and second-generation mTOR inhibitors, such as temsirolimus and everolimus, are safe and relatively well-tolerated, making them potentially attractive as single agents or in combination with conventional cytotoxics and other targeted therapies. Promising early clinical data suggests activity of mTOR inhibitors in a number of haematological diseases, including acute lymphoblastic leukaemia, chronic myeloid leukaemia, mantle cell lymphoma, anaplastic large cell lymphoma, and lymphoproliferative disorders. This review describes the rationale for using mTOR inhibitors in a variety of haematological diseases with a focus on their use in leukaemia.|Antineoplastic Agents/*therapeutic use[MESH]|Autoimmune Diseases/drug therapy/metabolism[MESH]|Hematologic Neoplasms/*drug therapy/metabolism[MESH]|Humans[MESH]|Leukemia/drug therapy/metabolism[MESH]|Lymphoproliferative Disorders/drug therapy/metabolism[MESH]|Protein Kinase Inhibitors/*therapeutic use[MESH]|Protein Kinases/*metabolism[MESH]|Signal Transduction/drug effects[MESH]|Sirolimus/*therapeutic use[MESH]|TOR Serine-Threonine Kinases[MESH] |